Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 8576179, 9 pages
https://doi.org/10.1155/2018/8576179
Research Article

Circulating Serum Level of Visfatin in Patients with Endometrial Cancer

1Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
2General Pathology Department, Pomeranian Medical University in Szczecin, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
3Department of Mathematics Applications in Economy, West Pomeranian University of Technology, Al. Piastów 17, 70-310 Szczecin, Poland

Correspondence should be addressed to Aneta Cymbaluk-Płoska; lp.atad@catena

Received 30 August 2017; Revised 22 October 2017; Accepted 28 November 2017; Published 4 January 2018

Academic Editor: Koichiro Wada

Copyright © 2018 Aneta Cymbaluk-Płoska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Aune, A. Sen, and L. J. Vatten, “Hypertension and the risk of endometrial cancer: A systematic review and meta-analysis of case-control and cohort studies,” Scientific Reports, vol. 7, Article ID 44808, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ni, T. Zhu, L. Zhao et al., “Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma,” Clinical and Translational Oncology, vol. 17, no. 10, pp. 835–839, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, “Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies,” The Lancet, vol. 371, no. 9612, pp. 569–578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Booth, A. Magnuson, J. Fouts, and M. Foster, “Adipose tissue, obesity and adipokines: role in cancer promotion,” Hormone Molecular Biology and Clinical Investigation, vol. 21, no. 1, pp. 57–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Ye, “Emerging role of adipose tissue hypoxia in obesity and insulin resistance,” International Journal of Obesity, vol. 33, no. 1, pp. 54–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. Q. He, Z. Gao, J. Yin, J. Zhang, Z. Yun, and J. Ye, “Regulation of HIF-1α activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia,” American Journal of Physiology-Endocrinology and Metabolism, vol. 300, no. 5, pp. E877–E885, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Jiang, A. Qu, T. Matsubara et al., “Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice,” Diabetes, vol. 60, no. 10, pp. 2484–2495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Galli, M. Piroddi, C. Annetti, C. Aisa, E. Floridi, and A. Floridi, “Oxidative stress and reactive oxygen species,” Contributions to Nephrology, vol. 149, pp. 240–260, 2005. View at Google Scholar · View at Scopus
  9. W. Wu, J. Li, M. Zhao, and X. Liu, “HIF-1α mediates visfatin-induced CTGF expression in vascular endothelial cells,” Cellular and Molecular Biology, vol. 63, no. 4, pp. 28–32, 2017. View at Publisher · View at Google Scholar
  10. M. M. Braun, E. A. Overbeek-Wager, and R. J. Grumbo, “Diagnosis and management of endometrial cancer,” American Family Physician, vol. 93, no. 6, pp. 468–474, 2016. View at Google Scholar · View at Scopus
  11. M. Uzunlulu, O. Telci Caklili, and A. Oguz, “Association between Metabolic Syndrome and Cancer,” Annals of Nutrition and Metabolism, vol. 68, no. 3, pp. 173–179, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Samal, Y. Sun, G. Stearns, C. Xie, S. Suggs, and I. Mcniece, “Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor,” Molecular and Cellular Biology, vol. 14, no. 2, pp. 1431–1437, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. W. H.-H. Sheu, T.-M. Chang, W.-J. Lee et al., “Effect of weight loss on proinflammatory state of mononuclear cells in obese women,” Obesity, vol. 16, no. 5, pp. 1033–1038, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Chang, D. Chang, K. Lin, S. Shin, and Y. Lee, “Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 6, pp. 515–527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. R. Moschen, A. Kaser, B. Enrich et al., “Visfatin, an adipocytokine with proinflammatory and immunomodulating properties,” The Journal of Immunology, vol. 178, no. 3, pp. 1748–1758, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Luk, Z. Malam, and J. C. Marshall, “Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity,” Journal of Leukocyte Biology, vol. 83, no. 4, pp. 804–816, 2008. View at Publisher · View at Google Scholar
  17. S. H. Jia, Y. Li, J. Parodo et al., “Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis,” The Journal of Clinical Investigation, vol. 113, no. 9, pp. 1318–1327, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. H. Jarrar, A. Baranova, R. Collantes et al., “Adipokines and cytokines in non-alcoholic fatty liver disease,” Alimentary Pharmacology & Therapeutics, vol. 27, no. 5, pp. 412–421, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Samara, M. Pfister, B. Marie, and S. Visvikis-Siest, “Visfatin, low-grade inflammation and body mass index (BMI),” Clinical Endocrinology, vol. 69, no. 4, pp. 568–574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Otero, R. Logo, R. Gomez et al., “Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1198–1201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. T. D. Filippatos, C. S. Derdemezis, I. F. Gazi et al., “Increased plasma visfatin levels in subjects with the metabolic syndrome [3],” European Journal of Clinical Investigation, vol. 38, no. 1, pp. 71-72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. H. J. Kim, Y. S. Lee, E. H. Won et al., “Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation,” BJU International, vol. 108, no. 2b, pp. E77–E83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. T. Patel, T. Mistry, J. E. P. Brown et al., “A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis,” Peptides, vol. 31, no. 1, pp. 51–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Li, Y. Zhang, B. Dorweiler et al., “Extracellular nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism,” The Journal of Biological Chemistry, vol. 283, no. 50, pp. 34833–34843, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-C. Lee, Y.-H. Yang, J.-H. Su, H.-L. Chang, M.-F. Hou, and S.-S. F. Yuan, “High visfatin expression in breast cancer tissue is associated with poor survival,” Cancer Epidemiology, Biomarkers & Prevention, vol. 20, no. 9, pp. 1892–1901, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. A. A. K. Folgueira, D. M. Carraro, H. Brentani et al., “Gene expression profile associated with response to doxorubicin-based therapy in breast cancer,” Clinical Cancer Research, vol. 11, no. 20, pp. 7434–7443, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Wang, C. Gao, Y. Zhang et al., “Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways,” Gynecologic Oncology, vol. 143, no. 1, pp. 168–178, 2016. View at Publisher · View at Google Scholar
  28. T. T. Ilhan, A. Kebapcilar, S. A. Yilmaz et al., “Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 11, pp. 4503–4508, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. S. N. Avcioglu, S. O. Altinkaya, M. Küçük, H. Yüksel, I. K. Ömürlü, and S. Yanik, “Visfatin concentrations in patients with endometrial cancer,” Gynecological Endocrinology, vol. 31, no. 3, pp. 202–207, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Tian, Y. Zhu, Y. Wang et al., “Visfatin, a potential biomarker and prognostic factor for endometrial cancer,” Gynecologic Oncology, vol. 129, no. 3, pp. 505–512, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Y. Tian, Y. M. Wang, Y. F. Zhang, and F. X. Xue, “The research advances in the relationship between visfatin and cancer,” Zhonghua Zhong Liu Za Zhi, vol. 39, no. 5, pp. 321–324, 2017. View at Google Scholar
  32. P. Luhn, C. M. Dallal, J. M. Weiss et al., “Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial,” Cancer Epidemiology, Biomarkers & Prevention, vol. 22, no. 7, pp. 1304–1312, 2013. View at Publisher · View at Google Scholar · View at Scopus